<DOC>
	<DOCNO>NCT01118013</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy , busulfan fludarabine phosphate , peripheral blood stem cell transplant help stop growth cancer cell . It may also stop patient 's immune system reject donor 's stem cell . Sometimes transplanted cell donor make immune response body 's normal cell . Giving methotrexate , tacrolimus , antithymocyte globulin transplant may stop happen . Once donated stem cell begin work , patient 's immune system may see remain cancer cell belong patient 's body destroy ( call graft-versus-tumor effect ) . Giving infusion donor 's white blood cell ( donor lymphocyte infusion ) may boost effect . PURPOSE : This phase II trial study well donor stem cell transplant work treat patient relapse hematologic malignancy secondary myelodysplasia previously treat high-dose chemotherapy autologous stem cell transplant .</brief_summary>
	<brief_title>Donor Stem Cell Transplant Treating Patients With Relapsed Hematologic Malignancies Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy Autologous Stem Cell Transplant</brief_title>
	<detailed_description>OBJECTIVES : Primary - To demonstrate efficacy perform reduced-intensity conditioning allogeneic hematopoietic cell transplantation patient relapse hematologic malignancy secondary myelodysplasia completion prior high-dose chemotherapy autologous hematopoietic stem cell transplantation . - To compare strategy regimen strategy use CALGB-100002 . Secondary - To describe response rate 6 12 month patient treat regimen . - To describe time-to-progression patient treated regimen . - To determine ability use pharmacokinetic-directed busulfan achieve AUC within 20 % target AUC &gt; 80 % patient . - To determine percent donor chimerism T-cell , myeloid B-cell population achieve regimen compare CALGB-100002 . - To determine risk acute chronic graft-versus-host disease toxicity regimen patient . - To describe overall survival disease-free survival patient treat regimen . - To determine rate viral , bacterial , fungal opportunistic infection occur first year transplantation compare CALGB-100002 . OUTLINE : This multicenter study . - Preparative Regimen : - Busulfan test dose : Patients receive busulfan IV 45 minute day -14 -9 . - Busulfan treatment dose : Patients receive fludarabine phosphate IV 30 minute day -7 -3 busulfan IV 3 hour day -6 -3 . - Graft-vs-Host Disease ( GVHD ) Prophylaxis : - HLA-identical donor : Patients receive antithymocyte globulin IV 6-10 hour day -6 -5 ; oral tacrolimus twice daily day -2 90 follow taper* tolerate day 150 180 ; methotrexate IV day 1 , 3 , 6 . NOTE : * Tacrolimus may taper day 60-90 donor chimerism CD3+ cell &lt; 50 % day 60 patient progressive disease . - Matched-unrelated donor : Patients receive antithymocyte globulin , tacrolimus , methotrexate HLA-identical donor regimen . Patients also receive oral mycophenolate mofetil twice daily day 0 60 . - Allogeneic Stem Cell Transplantation : Patients undergo allogeneic peripheral blood stem cell transplantation day 0 1 . Patients receive filgrastim subcutaneously daily begin day 7 continue blood count recover . - Donor Lymphocyte Infusion ( DLI ) : After day 180 ( day 210 patient without HLA-identical donor ) , patient stable progressive disease active GVHD may receive 3 DLIs every 8 week . Blood sample collect baseline periodically study therapy pharmacokinetic study . After completion study therapy , patient follow every 3 month 2 year every 6 month 5½ year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm hematologic malignancy : Chronic lymphocytic leukemia ( CLL ) prolymphocytic leukemia ( PLL ) Absolute lymphocytosis &gt; 5,000/μL Lymphocytes must appear morphologically mature &lt; 55 % prolymphocytes ( CLL ) Patients &gt; 55 % prolymphocytes consider PLL Lymphocyte phenotype expression CD20 , CD19 , CD5 ( CLL ) NonHodgkin lymphoma Any WHO classification histologic subtype Core biopsy acceptable primary diagnosis immunophenotyping Bone marrow biopsy sole mean diagnosis allow follicular lymphoma Hodgkin lymphoma Any WHO classification histologic subtype Core biopsy acceptable primary diagnosis immunophenotyping Bone marrow biopsy require Multiple myeloma Patients must active disease require treatment ( DurieSalmon stage IIII ) Acute myeloid leukemia Must &lt; 10 % bone marrow blast circulate blast Myelodysplastic syndrome ( MDS ) MDS define WHO criteria Must &lt; 10 % marrow blast Relapsed progressive disease myelodysplasia ≥ 6 month prior highdose chemotherapy autologous hematopoietic cell support Prior syngeneic transplantation allow Healthy donor meet one follow criterion : HLAidentical sibling ( 6/6 ) Serologic type class I ( A , B ) molecular type class II ( DRB1 ) require 8/8 matchedunrelated donor Molecular identity HLA A , B , C , DRB1 highresolution type require No syngeneic donor PATIENT CHARACTERISTICS : Creatinine clearance ≥ 40 mL/min Total bilirubin ≤ 2 mg/dL AST ≤ 3 time upper limit normal Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception DLCO ≥ 40 % symptomatic pulmonary disease LVEF ≥ 30 % MUGA ECHO No uncontrolled diabetes mellitus active serious infection No known hypersensitivity E.coliderived product No HIV infection PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 4 week elapse prior standard cytotoxic chemotherapy , radiation therapy , surgery plan start preparative regimen day 7</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>juvenile myelomonocytic leukemia</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood grade III lymphomatoid granulomatosis</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>childhood diffuse large cell lymphoma</keyword>
	<keyword>childhood grade III lymphomatoid granulomatosis</keyword>
	<keyword>childhood immunoblastic large cell lymphoma</keyword>
	<keyword>childhood nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>post-transplant lymphoproliferative disorder</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
	<keyword>recurrent childhood anaplastic large cell lymphoma</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>childhood acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>childhood acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>childhood acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>childhood acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>childhood acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>childhood acute monoblastic leukemia ( M5a )</keyword>
	<keyword>childhood acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult erythroleukemia ( M6a )</keyword>
	<keyword>adult pure erythroid leukemia ( M6b )</keyword>
	<keyword>childhood acute erythroleukemia ( M6 )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>childhood acute megakaryocytic leukemia ( M7 )</keyword>
	<keyword>childhood Burkitt lymphoma</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL1 negative</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>cutaneous B-cell non-Hodgkin lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
</DOC>